Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-cand-3_16-cv-00001/USCOURTS-cand-3_16-cv-00001-0/pdf.json

Nature of Suit Code: 890
Nature of Suit: Other Statutory Actions
Cause of Action: 15:0045 Federal Trade Commission Act

---

STIPULATED FINAL JUDGMENT AND ORDER

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

JONATHAN E. NUECHTERLEIN 

General Counsel 

MICHELLE RUSK, DC Bar No. 384850 

ANNETTE SOBERATS, FL Bar No. 0093934 

MARY JOHNSON, DC Bar No. 455345 

Federal Trade Commission 

600 Pennsylvania Avenue, NW 

Mail Drop CC-10528 

Washington, DC 20580 

Email: mrusk@ftc.gov; asoberats@ftc.gov; mjohnson1@ftc.gov 

Tel: (202) 326-3148, -2921, -3115 

Fax: (202) 326-3259 

Attorneys for Plaintiff 

FEDERAL TRADE COMMISSION 

UNITED STATES DISTRICT COURT 

FOR THE NORTHERN DISTRICT OF CALIFORNIA 

San Francisco Division 

FEDERAL TRADE COMMISSION, 

 Plaintiff, 

v. 

LUMOS LABS, INC., a corporation 

d/b/a LUMOSITY 

and 

KUNAL SARKAR, and 

MICHAEL SCANLON, 

Individually and as officers of LUMOS 

LABS, INC. 

Defendants. 

Case No. 3:16-cv-00001-sk 

STIPULATED FINAL 

JUDGMENT AND ORDER FOR 

PERMANENT INJUNCTION AND 

OTHER EQUITABLE RELIEF 

Plaintiff, the Federal Trade Commission (“Commission” or “FTC”), filed its Complaint 

for Permanent Injunction and Other Equitable Relief (“Complaint”) against Defendants Lumos 

Labs, Inc. d/b/a Lumosity, Kunal Sarkar, and Michael Scanlon, pursuant to Section 13(b) of the 

Federal Trade Commission Act (“FTC Act”), 15 U.S.C. § 53(b), alleging unfair or deceptive acts 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 1 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 2

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

or practices and false advertisements in violation of Sections 5(a) and 12 of the FTC Act, 15 

U.S.C. §§ 45(a) and 52. 

The Commission and Defendants stipulate to the entry of this Order for Permanent 

Injunction and Other Equitable Relief (“Order”) to resolve all matters in dispute in this action 

between them.

THEREFORE, IT IS ORDERED as follows: 

FINDINGS

1. This Court has jurisdiction over this matter. 

2. The Complaint charges that Defendants participated in deceptive acts or practices and 

false advertisements in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 

52, in connection with the deceptive marketing of a brain-training program.

3. Defendants neither admit nor deny any of the allegations in the Complaint, except as 

specifically stated in this Order. Only for purposes of this action, Defendants admit the facts 

necessary to establish jurisdiction. 

4. Defendants waive any claim that they may have under the Equal Access to Justice Act, 

28 U.S.C. § 2412, concerning the prosecution of this action through the date of this Order, and 

agree to bear their own costs and attorney fees.

5. Defendants and the Commission waive all rights to appeal or otherwise challenge or 

contest the validity of this Order.

ORDER

DEFINITIONS

For the purpose of this Order, the following definitions apply: 

1. “Defendants” means both of the Individual Defendants and the Corporate Defendant, 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 2 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 3 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

individually, collectively, or in any combination. 

2. “Corporate Defendant” means Lumos Labs, Inc. d/b/a Lumosity and its successors and 

assigns.

3. “Individual Defendants” means Kunal Sarkar and Michael Scanlon.

4. “Commerce” means as defined in Section 4 of the FTC Act, 15 U.S.C. § 44. 

5. “Covered Product” means the Lumosity Program and LumiKids and any product, 

program, device, or service for children or adults that purports to alter the brain’s structure or 

function; improve cognitive abilities or provide benefits from improved cognitive abilities, 

including improved performance on everyday tasks, in school, at work, or in athletics; treat, 

mitigate, prevent, or delay the onset of cognitive impairment or disorders, including cognitive 

impairment related to aging; or provide an assessment of cognitive abilities. 

6. “Clearly and Conspicuously” means that a required disclosure is difficult to miss (i.e., 

easily noticeable) and easily understandable by ordinary consumers, including in all of the 

following ways: 

a. In any communication that is solely visual or solely audible, the disclosure must 

be made through the same means through which the communication is presented. In any 

communication made through both visual and audible means, such as a television advertisement, 

the disclosure must be presented simultaneously in both the visual and audible portions of the 

communication, even if the representation requiring the disclosure is made in only one means.

b. A visual disclosure, by its size, contrast, location, the length of time it appears, 

and other characteristics, must stand out from any accompanying text or other visual elements so 

that it is easily noticed, read, and understood. 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 3 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 4 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

c. An audible disclosure, including by telephone or streaming video, must be 

delivered in a volume, speed, and cadence sufficient for ordinary consumers to easily hear and 

understand it. 

 d. In any communication using an interactive electronic medium, such as the 

Internet or software, the disclosure must be unavoidable. 

e. The disclosure must use diction and syntax understandable to ordinary consumers 

and must appear in each language in which the representation that requires the disclosure 

appears.

f. The disclosure must comply with these requirements in each medium through 

which it is received, including all electronic devices and face-to-face communications. 

g. The disclosure must not be contradicted or mitigated by, or inconsistent with, 

anything else in the communication. 

When representations or sales practices target a specific audience, such as children, the elderly, 

or the terminally ill, “ordinary consumers” includes reasonable members of that group. 

7. “Endorsement” means any advertising message (including verbal statements, 

demonstrations, or depictions of the name, signature, likeness or other identifying personal 

characteristics of an individual or the name or seal of an organization) that consumers are likely 

to believe reflects the opinions, beliefs, findings, or experiences of a party other than the 

sponsoring advertiser, even if the views expressed by that party are identical to those of the 

sponsoring advertiser. The party whose opinions, beliefs, findings, or experience the message 

appears to reflect will be called the endorser and may be an individual, group, or institution. 

8. “Lumosity Program” means the Lumosity personalized brain training program and 

related assessment measures, available online and through mobile apps, and consisting of a 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 4 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 5 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

variety of games targeting cognitive abilities such as memory, attention, speed, flexibility, and 

problem solving. 

9. “Material Connection” means any relationship that materially affects the weight or 

credibility of any endorsement and that would not be reasonably expected by consumers.

10. “Person” means a natural person, an organization, or other legal entity, including a 

corporation, partnership, sole proprietorship, limited liability company, association, cooperative, 

or any other group or combination acting as an entity. 

11. “Reliably Reported,” for a human clinical test or study (“test”), means a report of the 

test has been published in a peer-reviewed journal, and such published report provides sufficient 

information about the test for experts in the relevant field to assess the reliability of the results.

I. PROHIBITED REPRESENTATIONS: IMPROVING PERFORMANCE AT 

SCHOOL, AT WORK, AND IN ATHLETICS; DELAYING AGE-RELATED DECLINE; 

AND REDUCING COGNITIVE IMPAIRMENT

IT IS ORDERED that Defendants, Defendants’ officers, agents, servants, employees, 

and attorneys, and all other persons in active concert or participation with any of them, who 

receive actual notice of this Order, whether acting directly or indirectly, in connection with the 

manufacturing, labeling, advertising, promotion, offering for sale, sale or distribution of any 

Covered Product, are permanently restrained and enjoined from making any representation, 

expressly or by implication, that using such Covered Product: 

A. improves performance in school, at work, or in athletics; 

B. delays or protects against age-related decline in memory or other cognitive 

function, including mild cognitive impairment, dementia, or Alzheimer’s disease; or

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 5 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 6 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

C. reduces cognitive impairment caused by health conditions, including Turner 

syndrome, post-traumatic stress disorder (PTSD), attention deficit hyperactivity disorder 

(ADHD), traumatic brain injury (TBI), stroke, or side effects of chemotherapy, 

unless the representation is non-misleading, and, at the time such representation is made, 

Defendants possess and rely upon competent and reliable scientific evidence to substantiate that 

the representation is true. 

For purposes of this Section, competent and reliable scientific evidence shall consist of 

human clinical testing of such product that is sufficient in quality and quantity, based on 

standards generally accepted by experts in the relevant field, when considered in light of the 

entire body of relevant and reliable scientific evidence, to substantiate that the representation is 

true. Such testing shall be (1) randomized, adequately controlled, and blinded to the maximum 

extent practicable; and (2) be conducted by researchers qualified by training and experience to 

conduct such testing. In addition, all underlying or supporting data and documents generally 

accepted by experts in the relevant field as relevant to an assessment of such testing as described 

in the Section XIII, titled Preservation of Records Relating to Competent and Reliable Human 

Clinical Tests or Studies, must be available for inspection and production to the Commission. 

II. PROHIBITED REPRESENTATIONS: OTHER BENEFITS

IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, servants, 

employees, and attorneys, and all other persons in active concert or participation with any of 

them, who receive actual notice of this Order, whether acting directly or indirectly, in connection 

with the manufacturing, labeling, advertising, promotion, offering for sale, sale or distribution of 

any Covered Product, are permanently restrained and enjoined from making, expressly or by 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 6 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 7 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

implication, any representation, other than representations covered under Section I of this Order, 

about the benefits or efficacy of any Covered Product, including performance on everyday tasks, 

unless the representation is non-misleading, and, at the time of making such representation, 

Defendants possess and rely upon competent and reliable scientific evidence that is sufficient in 

quality and quantity based on standards generally accepted in the relevant scientific fields, when 

considered in light of the entire body of relevant and reliable scientific evidence, to substantiate 

that the representation is true. 

For purposes of this Section, competent and reliable scientific evidence means tests, 

analyses, research, or studies (1) that have been conducted and evaluated in an objective manner 

by qualified persons; (2) that are generally accepted in the profession to yield accurate and 

reliable results; and (3) as to which, when they are human clinical tests or studies, all underlying 

or supporting data and documents generally accepted by experts in the field as relevant to an

assessment of such testing as set forth in the Section XIII, titled Preservation of Records Relating 

to Competent and Reliable Human Clinical Tests or Studies, are available for inspection and 

production to the Commission. 

III. PROHIBITED REPRESENTATIONS: TESTS OR STUDIES

IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, servants, 

employees, and attorneys, and all other persons in active concert or participation with any of 

them, who receive actual notice of this Order, whether acting directly or indirectly, in connection 

with the manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of 

any Covered Product, are permanently restrained and enjoined from misrepresenting, in any 

manner, expressly or by implication:

A. The existence, contents, validity, results, conclusions, or interpretations of any 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 7 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 8 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

test, study, or research involving any Covered Product; or 

B. That the benefits of any Covered Product are scientifically proven. 

IV. FDA APPROVED CLAIMS

IT IS FURTHER ORDERED that nothing in this Order shall prohibit Defendants from: 

A. Making any representation for any drug that is permitted in labeling for such drug 

under any tentative or final monograph promulgated by the Food and Drug Administration, or 

under any new drug application approved by the Food and Drug Administration; or 

B. Making any representation for any product that is specifically permitted in 

labeling for such product by regulations promulgated by the Food and Drug Administration 

pursuant to the Nutrition Labeling and Education Act of 1990 or permitted under Sections 303-

304 of the Food and Drug Administration Modernization Act of 1997.

V. PROHIBITIONS CONCERNING ENDORSEMENTS

IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, servants, 

employees, and attorneys, and all other persons in active concert or participation with any of 

them, who receive actual notice of this Order, whether acting directly or indirectly, in connection 

with the manufacturing, labeling, advertising, promotion, offering for sale, sale or distribution of 

any Covered Product, are permanently restrained and enjoined from: 

A. Misrepresenting, in any manner, expressly or by implication, that an Endorsement 

of any Covered Product represents the opinions, findings, beliefs, or experience of the Person 

providing the Endorsement; and 

B. Failing to disclose, Clearly and Conspicuously, a Material Connection, if one 

exists, between the Person providing the Endorsement and Defendants, including but not limited 

to the use of a contest with prizes to solicit such Endorsement. 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 8 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 9 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

VI. MONETARY JUDGMENT

IT IS FURTHER ORDERED that: 

A. Judgment in the amount of Fifty Million Dollars ($50,000,000.00) is entered in 

favor of the Commission against Corporate Defendant as equitable monetary relief.

B. Corporate Defendant is ordered to pay to the Commission Two Million Dollars 

($2,000,000.00), which, as Corporate Defendant stipulates, its undersigned counsel holds in 

escrow for no purpose other than payment to the Commission. Such payment must be made 

within seven (7) days of entry of this Order by electronic fund transfer in accordance with 

instructions previously provided by a representative of the Commission. Upon such payment, 

the remainder of the judgment is suspended, subject to the Subsections below. 

C. The Commission’s agreement to the suspension of part of the judgment is 

expressly premised upon the truthfulness, accuracy, and completeness of Corporate Defendant’s 

audited and unaudited financial statements and related documents (collectively, “financial 

representations”) submitted to the Commission, namely: 

 1. The 2012 U.S. Corporate Income Tax Declaration for an IRS e-file Return 

signed by Krishna Kakarala, Chief Financial Officer, dated September 16, 2013, including the 

attachments;

 2. The 2013 U.S. Corporate Income Tax Declaration for an IRS e-file Return 

signed by Krishna Kakarala, Chief Financial Officer, dated September 11, 2014, including the 

attachments;

 3. The 2014 U.S. Corporate Income Tax Declaration for an IRS e-file Return

as Amended, signed by Krishna Kakarala, Chief Financial Officer, dated October 23, 2015, 

including the attachments; 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 9 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 10 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

 4. The audited Financial Statements of Corporate Defendant for the Years 

Ended December 31, 2013 and 2012, dated October 30, 2015, including the Independent 

Auditor’s Report and the notes to the financial statements; 

 5. The audited Financial Statements of Corporate Defendant for the Years 

Ended December 31, 2014 and 2013, dated October 30, 2015, including the Independent 

Auditor’s Report and the notes to the financial statements; 

 6. The unaudited Financial Statements of Corporate Defendant for the Period 

Ending March 31, 2015, dated October 30, 2015; and 

 7. The unaudited Financial Statements of Corporate Defendant for the Period 

Ending June 30, 2015, dated October 30, 2015. 

D. The suspension of the judgment will be lifted as to the Corporate Defendant if, 

upon motion by the Commission, the Court finds that the Corporate Defendant failed to disclose 

any material asset, materially misstated the value of any asset, or made any other material 

misstatement or omission in the financial representations identified above.

E. If the suspension of the judgment is lifted, the judgment becomes immediately 

due as to the Corporate Defendant in the amount specified in Subsection A above (which the 

parties stipulate only for purposes of this Section represents consumer injury), less any payment 

previously made pursuant to this Section, plus interest computed from the date of entry of this 

Order. 

VII. ADDITIONAL MONETARY PROVISIONS

IT IS FURTHER ORDERED that:

A. Defendants relinquish dominion and all legal and equitable right, title, and interest 

in all assets transferred pursuant to this Order and may not seek the return of any assets. 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 10 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 11 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

B. The facts alleged in the Complaint will be taken as true, without further proof, in 

any subsequent civil litigation by or on behalf of the Commission in a proceeding to enforce its 

rights to any payment or monetary judgment pursuant to this Order, such as a 

nondischargeability complaint in any bankruptcy case.

C. The facts alleged in the Complaint establish all elements necessary to sustain an 

action by the Commission pursuant to Section 523(a)(2)(A) of the Bankruptcy Code, 11 U.S.C. 

§ 523(a)(2)(A), and this Order will have collateral estoppel effect for such purposes. 

D. Corporate Defendant acknowledges that its Taxpayer Identification Number 

(Employer Identification Number), which Corporate Defendant previously submitted to the 

Commission, may be used for collecting and reporting on any delinquent amount arising out of 

this Order, in accordance with 31 U.S.C. § 7701. 

E. All money paid to the Commission pursuant to this Order may be deposited into a 

fund administered by the Commission or its designee to be used for equitable relief, including 

consumer redress and any attendant expenses for the administration of any redress fund. If a 

representative of the Commission decides that direct redress to consumers is wholly or partially 

impracticable or money remains after redress is completed, the Commission may apply any 

remaining money for such other equitable relief (including consumer information remedies) as it 

determines to be reasonably related to Defendants’ practices alleged in the Complaint. Any 

money not used for such equitable relief is to be deposited to the United States Treasury as 

disgorgement. Defendants have no right to challenge any actions the Commission or its 

representatives may take pursuant to this Subsection. 

VIII. REQUIREMENT TO PROVIDE CUSTOMER LIST

IT IS FURTHER ORDERED that Corporate Defendant, its officers, agents, servants, 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 11 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 12 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

employees, and attorneys, and all other persons in active concert or participation with any of 

them, shall within fourteen (14) days provide a list of all customers who subscribed to the 

Lumosity Program between January 1, 2009 and December 31, 2014, to the extent such 

information is in their possession, custody, or control. The list shall be in searchable and 

sortable electronic format and shall include, but not be limited to, the following information for 

each customer: name, email address, date customer first subscribed, type of subscription, and 

total dollar amount paid over the course of the subscription. If a representative of the 

Commission requests in writing any additional information related to redress, Corporate 

Defendant must provide all such information in its possession, custody, and control, in the form 

prescribed by the Commission, within fourteen (14) days. 

IX. NOTICE TO SUBSCRIBERS ON AUTO-RENEWAL PLAN

IT IS FURTHER ORDERED that Corporate Defendant shall provide adequate and 

timely notice of this Order by email and in the web and mobile versions of the Lumosity 

Program to all current Lumosity subscribers in the United States who subscribed to the Lumosity 

Program at any time from January 1, 2009 until December 31, 2014 and who participate in a plan 

that is set to automatically renew at the end of its term. Such notice shall provide a link, directly 

when possible, or through one interim login page when a direct link is not possible, to an account 

setting page that Clearly and Conspicuously displays a one-step mechanism for cancelling the 

auto-renewal feature. For purposes of this Section, adequate and timely notice shall mean:

A. An email, sent within seven (7) days of the entry of this Order, in the exact 

wording and format set forth in Attachment A with the subject line “Important Notice – Your 

Lumosity Subscription Bill” and without any other materials accompanying the email; 

B. A full-page web screen, posted within seven (7) days of the entry of this Order, in 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 12 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 13 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

the exact wording and format in Attachment B, that appears on the Lumosity website 

immediately after the subscriber logs in and prior to access to any Lumosity games and remains 

on the website for a period of ninety (90) days from initial posting or until the subscriber replies

by clicking on a link in the email, web, or mobile notice described in Subsections A – C of this 

Section, whichever comes first; and

C. A full-page mobile app screen, made available to subscribers through an app 

update that is made available in a timely manner and no later than thirty (30) days from entry of 

this Order, in the exact wording set forth in Attachment B and in an easily legible format 

consistent with the format set forth in Attachment B, that appears in the Lumosity mobile apps 

for the Apple and Google Play platforms prior to access to any Lumosity games and remains in 

the mobile app for a period of ninety (90) days from initial posting or until the subscriber replies 

by clicking on a link in the email, web, or mobile notice described in Subsections A – C of this 

Section, whichever comes first. To ensure timely availability of the mobile app screen pursuant 

to this Subsection, the Corporate Defendant shall submit the necessary update of its app to Apple 

and Google Play within fourteen (14) days of entry of this Order and request expedited review 

and approval. 

X. ORDER ACKNOWLEDGMENTS

IT IS FURTHER ORDERED that Defendants obtain acknowledgments of receipt of 

this Order:

A. Each Defendant, within seven (7) days of entry of this Order, must submit to the 

Commission an acknowledgment of receipt of this Order sworn under penalty of perjury. 

B. For three (3) years after entry of this Order, each Individual Defendant for any 

business that such Defendant, individually or collectively with any other Defendants, is the 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 13 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 14 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

majority owner or directly or indirectly controls, and each Corporate Defendant, must deliver a 

copy of this Order to: (1) all principals, officers, directors, LLC managers and members, 

employees, agents, and representatives who participate in conduct related to the subject matter of 

the Order; and (2) any business entity resulting from any change in structure as set forth in 

Section XI, titled Compliance Reporting. Delivery must occur within seven (7) days of entry of 

this Order for current personnel. For all others, delivery must occur before they assume their 

responsibilities.

C. From each individual or entity to which a Defendant delivered a copy of this 

Order, that Defendant must obtain, within thirty (30) days, a signed and dated acknowledgment 

of receipt of this Order.

XI. COMPLIANCE REPORTING

IT IS FURTHER ORDERED that Defendants make timely submissions to the 

Commission:

A. Sixty (60) days after entry of this Order, each Defendant must submit a 

compliance report, sworn under penalty of perjury. 

 1. Each Defendant must: (a) designate at least one telephone number and an 

email, physical, and postal address as points of contact, which representatives of the Commission 

may use to communicate with that Defendant; (b) identify all of that Defendant’s businesses by 

all of their names, telephone numbers, and email, Internet, physical, and postal addresses; (c) 

describe the activities of each business, including the products and services offered, the means of 

advertising, marketing, and sales, and the involvement of any other Defendant (which Individual 

Defendants must describe if they know or should know due to their own involvement); (d) 

describe in detail whether and how that Defendant is in compliance with each Section of this 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 14 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 15 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Order; and (e) provide a copy of each Order Acknowledgment obtained pursuant to this Order, 

unless previously submitted to the Commission; 

 2. Additionally, each Individual Defendant must: (a) identify all telephone 

numbers and all email, Internet, physical, and postal addresses, including all residences of such 

Defendant; (b) identify all titles and roles in each business for which such Defendant is an 

employee or consultant and any business in which such Defendant has direct or indirect control; 

and (c) describe in detail such Defendant’s involvement in each such business, including title, 

role, responsibilities, participation, authority, control, and any ownership. 

B. For ten (10) years following entry of this Order, each Defendant must submit a 

compliance notice, sworn under penalty of perjury, within sixty (60) days of any change in the 

following: 

 1. Each Corporate Defendant must report any change in: (a) any designated 

point of contact; or (b) the structure of the Corporate Defendant or any entity that the Corporate 

Defendant has any ownership interest in or directly or indirectly controls that may affect 

compliance obligations arising under this Order, including: the creation, merger, sale, or 

dissolution of the entity or any subsidiary, parent, or affiliate that engages in any acts or practices 

subject to this Order.

 2. Additionally, each Individual Defendant must report any change in: (a) 

name, including aliases or fictitious name, or residence address of such Defendant; or (b) title or 

role in each business for which such Defendant is an employee or consultant and each business

in which such Defendant has direct or indirect control, and identify the name, physical address, 

and any Internet address of the business or entity. 

C. Each Defendant must submit to the Commission notice of the filing of any 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 15 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 16 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

bankruptcy petition, insolvency proceeding, or similar proceeding by or against such Defendant 

within fourteen (14) days of its filing.

D. Any submission to the Commission required by this Order to be sworn under 

penalty of perjury must be true and accurate and comply with 28 U.S.C. § 1746, such as by 

concluding: “I declare under penalty of perjury under the laws of the United States of America 

that the foregoing is true and correct. Executed on:_____” and supplying the date, signatory’s 

full name, title (if applicable), and signature. 

E. Unless otherwise directed by a Commission representative in writing, all 

submissions to the Commission pursuant to this Order must be emailed to DEbrief@ftc.gov or 

sent by overnight courier (not the U.S. Postal Service) to: Associate Director for Enforcement, 

Bureau of Consumer Protection, Federal Trade Commission, 600 Pennsylvania Avenue NW, 

Washington, D.C. 20580. The subject line must begin: FTC v. Lumos Labs, Inc., et al. No. 132-

3212. 

XII. RECORDKEEPING

IT IS FURTHER ORDERED that Defendants must create certain records for ten (10) 

years after entry of this Order, and retain each such record for five (5) years. Specifically, 

Corporate Defendant and each Individual Defendant for any business that such Defendant, 

individually or collectively with any other Defendants, is a majority owner or directly or 

indirectly controls, must create and retain the following records: 

A. Accounting records showing the revenues from all products or services sold, all 

costs incurred in generating those revenues, and the resulting net profit or loss; 

B. Personnel records showing, for each person providing services, whether as an 

employee or otherwise, that person’s: name, addresses, and telephone numbers; job title or 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 16 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 17 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

position; dates of service; and, if applicable, the reason for termination; 

C. Complaints and refund requests, whether received directly or referred from a third 

party, and any response, in connection with any Covered Product; 

D. All records necessary to demonstrate full compliance with each provision of this 

Order, including all submissions to the Commission; 

E. A copy of each unique advertisement or other marketing material for any Covered 

Product; and

F. All records, in the Corporate Defendant’s possession, custody, or control, 

necessary to demonstrate the provision of notice pursuant to Section IX of this Order and the 

cancellation of subscriptions pursuant to Section IX. 

XIII. PRESERVATION OF RECORDS RELATING TO COMPETENT AND 

RELIABLE HUMAN CLINICAL TESTS OR STUDIES

IT IS FURTHER ORDERED that, with regard to any human clinical test or study 

(“test”) upon which Defendants rely to substantiate any claim covered by this Order, Defendants 

shall secure and preserve all underlying or supporting data and documents generally accepted by 

experts in the field as relevant to an assessment of the test, including, but not necessarily limited 

to: 

A. All protocols and protocol amendments, reports, articles, write-ups, or other 

accounts of the results of the test, and drafts of such documents reviewed by the test sponsor or 

any other person not employed by the research entity; 

B. All documents referring or relating to recruitment; randomization; instructions, 

including oral instructions, to participants; and participant compliance; 

C. Documents sufficient to identify all test participants, including any participants 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 17 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 18 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

who did not complete the test, and all written or recorded communications with any participants 

relating to the test; all raw data collected from participants enrolled in the test, including any 

participants who did not complete the test; source documents for such data; any data dictionaries; 

and any case report forms; 

D. All documents referring or relating to any statistical analysis of any test data, 

including, but not limited to, any pretest analysis, intent-to-treat analysis, or between-group 

analysis performed on any test data; and

E. All documents referring or relating to the sponsorship of the test, including all 

communications and contracts between any sponsor and the test’s researchers.

Provided, however, the preceding preservation requirement shall not apply to a Reliably 

Reported test, unless the test was conducted, controlled, or sponsored, in whole or in part by: (1) 

any Defendant; (2) any Defendant’s officers, agents, representatives, or employees; (3) any other 

person or entity in active concert or participation with any Defendant; or (4) any person or entity 

affiliated with or acting on behalf of any Defendant. 

 For any test conducted, controlled, or sponsored, in whole or in part, by Defendants, 

Defendants must establish and maintain reasonable procedures to protect the confidentiality, 

security, and integrity of any personal information collected from or about participants. These 

procedures shall be documented in writing and shall contain administrative, technical, and 

physical safeguards appropriate to Defendants’ size and complexity, the nature and scope of 

Defendants’ activities, and the sensitivity of the personal information collected from or about the 

participants.

XIV. COMPLIANCE MONITORING

IT IS FURTHER ORDERED that, for the purpose of monitoring Defendants’ 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 18 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 19 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

compliance with this Order:

A. Within fourteen (14) days of receipt of a written request from a representative of 

the Commission, each Defendant must: submit additional compliance reports or other requested 

information, which must be sworn under penalty of perjury; appear for depositions; and produce 

documents for inspection and copying. The Commission also is authorized to obtain discovery, 

without further leave of court, using any of the procedures prescribed by Federal Rules of Civil 

Procedure 29, 30 (including telephonic depositions), 31, 33, 34, 36, 45, and 69 provided that 

Defendants, after attempting to resolve a dispute without court action and for good cause shown, 

may file a motion with this Court seeking an order for one or more of the protections set forth in 

Rule 26(c). 

B. For matters concerning this Order, the Commission is authorized to communicate 

directly with each Defendant. Each Defendant must permit representatives of the Commission to 

interview any employee or other person affiliated with such Defendant who has agreed to such 

an interview. The person interviewed may have counsel present. 

 C. The Commission may use all other lawful means, including posing, through its 

representatives as consumers, suppliers, or other individuals or entities, to Defendants or any 

individual or entity affiliated with Defendants, without the necessity of identification or prior 

notice. Nothing in this Order limits the Commission’s lawful use of compulsory process, 

pursuant to Sections 9 and 20 of the FTC Act, 15 U.S.C. §§ 49, 57b-1. 

D. Upon written request from a representative of the Commission, any consumer 

reporting agency must furnish consumer reports concerning Individual Defendants, pursuant to 

Section 604(1) of the Fair Credit Reporting Act, 15 U.S.C. § 1681b(a)(1). 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 19 of 23
1 XV. RETENTION OF JURISDICTION 

2 

IT IS FURTHER ORDERED that this Court retains jurisdiction of this matter for 

3 

purposes of construction, modification, and enforcement of this Order. 

4 

5 SO ORDERED this_ day of ______ , 20 . 

6 

7 

8 UNITED STATES DISTRICT JUDGE 

9 lso STIPULATED AND AGREED: 

lo I 

::;7~ 13 MICHELLE RUSK I ~ ANNETTE SOBERATS 

MARY JOHNSON 

Federal Trade Commission 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

600 Pennsylvania A venue, NW 

Mail Drop CC-10528 

Washington, D.C. 20580 

Tel: 202-326-3148, - 2921 , - 3115; Fax: 202-326-3259 

mrusk@ftc.gov; asoberats@ftc.gov; mjohnsonl@ftc.gov 

Attorneys for Plaintiff 

FOR DEFENDANTS: 

LUMOS LABS, INC. 

140 New Montgomery Street, Floor 19 

San Francisco, California 94105 

;a 

~d~m = 

officer of Lumos Labs, Inc. 

STIPULATED FINAL JUDGMENT AND ORDER 

Date: l 1/1 ;;<_/J S 

r I 

Date: 11 lqlw1) I I 

Date: It/ t:t/ )..o\\. I I 

PAGE 20 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 20 of 23
1 

2 

Michael Scanlon individually and as an 

: a;2~Lav~ Date: ll { , ,._ \ l ~ 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

1 8 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

Lydia B. Parnes 

Margaret L. Lassack 

Wilson Sonsini Goodrich & Rosati 

1700 K Street, NW, Fifth Floor 

Washington, DC 20006 

Tel: (202) 973-8801 , -8806 

lpames@wsgr.com; mlassack@wsgr.com 

Attorneys for Lumos Labs, Inc. 

John Dfu2::::=-===- Date: I/ ;/p /; 

Brandon Myers 

Covington & Burling LLP 

One CityCenter 

850 Tenth Street, NW 

Washington, DC 20001 

Tel: (202) 662-5938; -5132 

jgraubert@cov.com; bmyers@cov.com 

Attorneys for Kunal Sarkar and Michael Scanlon 

Respectfully submitted, 

Dated: ----- MICHELLE RUSK 

ANNETTE SOBERATS 

MARY JOHNSON 

Attorneys for Plaintiff 

Federal Trade Commission 

STIPULATED FINAL JUDGMENT AND ORDER PAGE 21 

January 4, 2016 /s/ Michelle Rusk

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 21 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 22 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

ATTACHMENT A 

[EMAIL NOTICE]

SUBJECT LINE: IMPORTANT NOTICE – YOUR LUMOSITY SUBSCRIPTION BILL

Dear [Recipient Name]:

You currently have a Lumosity subscription with an auto-renewal feature – in other words, we 

automatically charge you to renew your subscription at the end of the current term unless you 

have turned off the auto-renewal. This notice is to let you know that we recently decided to 

settle a deceptive advertising lawsuit by the Federal Trade Commission (FTC), the nation’s 

consumer protection agency. The FTC charged us with making claims that were not supported 

by science, including claims that using Lumosity: 

• Improves performance in school, work, and athletics; 

• Delays age-related mental decline and protects against dementia and Alzheimer’s 

disease; and

• Helps those with ADHD, PTSD, Traumatic Brain Injury, and other health 

conditions. 

Visit the FTC website at [URL] to find out more about the FTC’s lawsuit.

To settle the case, we have agreed – among other things – to let you know that you can avoid 

future billing by turning off your auto-renewal. 

If you would like us to stop billing you, click here to go to your account 

settings and turn off your auto-renewal. 

You can also change your subscription at any time by going to your Account Settings page. 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 22 of 23
STIPULATED FINAL JUDGMENT AND ORDER PAGE 23 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

ATTACHMENT B

[INTERNET/MOBILE NOTICE: TO APPEAR AS FULL-PAGE SCREEN PRIOR TO 

ACCESS TO LUMOSITY GAMES]

IMPORTANT NOTICE – YOUR LUMOSITY SUBSCRIPTION BILL

Dear [Recipient Name]:

You currently have a Lumosity subscription with an auto-renewal feature – in other words, we 

automatically charge you to renew your subscription at the end of the current term unless you 

have turned off the auto-renewal. This notice is to let you know that we recently decided to settle 

a deceptive advertising lawsuit by the Federal Trade Commission (FTC), the nation’s consumer 

protection agency. The FTC charged us with making claims that were not supported by science, 

including claims that using Lumosity: 

• Improves performance in school, work, and athletics; 

• Delays age-related mental decline and protects against dementia and Alzheimer’s 

disease; and

• Helps those with ADHD, PTSD, Traumatic Brain Injury, and other health 

conditions. 

Visit the FTC website at [URL] to find out more about the FTC’s lawsuit.

To settle the case, we have agreed – among other things – to let you know that you can avoid 

future billing by turning off your auto-renewal. Please choose an option below: 

If you would like us to stop billing you, click here to go to your account 

settings and turn off your auto-renewal.

If you do not want to make changes to your billing at this time, click 

here to go to Lumosity.

If you would like to review this message again, we also have sent a copy to the email address on 

record for your Lumosity Account. 

Case 3:16-cv-00001-WHO Document 10 Filed 01/08/16 Page 23 of 23